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Differential expression of microRNAs (miRs) in the brain of patients with
neurodegenerative diseases suggests that they may have key regulatory roles in
the development of these disorders. Two such miRs, miR-7, and miR-153 have recently
been shown to target α-synuclein, a protein critically involved in the pathological process
of Parkinson’s disease. By using a well-established in culture Parkinson’s disease
model that of neurotoxin 1-Methyl-4-Phenyl-Pyridinium (MPP+), we examined whether
miR-7 and miR-153 display neuroprotective properties. Herein, we demonstrate that
treatment of cortical neurons with MPP+ induced a dose-dependent cell death with
apoptotic characteristics. This was reflected in altered intracellular signaling characterized
by increased levels of activated kinases p38MAPK and ERK1/2 and reduced levels
of activated AKT, p70S6K, and SAPK/JNK. Overexpression of miR-7 or miR-153 by
adenoviral transduction protected cortical neurons from MPP+-induced toxicity, restored
neuronal viability and anti-apoptotic BCL-2 protein levels while attenuated activation of
caspase-3. Moreover, both miR-7 and miR-153 interfered with MPP+-induced alterations
in intracellular signaling pathways in a partially overlapping manner; specifically, they
preserved activation of mTOR and SAPK/JNK signaling pathways in the MPP+-treated
neurons, while miR-153 also attenuated MPP+-induced activation of p38MAPK. No
major effects were observed in the rest of signaling cascades or proteins investigated.
Furthermore, the neuroprotective effect of miR-7 and miR-153 was alleviated when
MPP+ was co-administered with rapamycin. Taken together, our results suggest that
miR-7 and miR-153 protect neurons from cell death by interfering with the MPP+-induced
downregulation of mTOR signaling.
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INTRODUCTION
Parkinson’s disease (PD) is a heterogeneous neurodegenerative
disorder that affects 1% of the population aged over 65. It
perturbs both dopaminergic (substantia nigra pars compacta)
and non-dopaminergic (locus coeruleous, raphe nuclei, nucleus
basalis of Meynert, hypothalamus, pedunculopontine nucleus)
neuronal systems. Our current understanding of the disease
points toward a variety of genetic, cellular, and environmental
factors that independently or in combination cause progres-
sive neurodegeneration. These factors lead to oxidative stress,
abnormal protein degradation, autophagy, reduced protein syn-
thesis, and altered signal transduction that combined induce
neuronal death. Which of these mechanisms is more impor-
tant to PD pathogenesis and progression remains unknown
(Obeso et al., 2010). So far, epidemiological data and therapeutic
studies using neuroprotective substances such as caffeine, nico-
tine, ginsenosides, flavonoids, vitamins, and growth factors have
pointed out that drugs directed against a single molecular tar-
get are likely to be ineffective in treating the disease while agents
with multiple pharmacological targets appear more suitable.
Consistently, treatments with generic neuroprotective factors and
various combinations of approved drugs are now vigorously
explored (reviewed in Seidl and Potashkin, 2011; Mythri et al.,
2012; Rodnitzky, 2012; Santos, 2012; Kordower and Bjorklund,
2013).
microRNAs (miRs) are a class of highly conserved small, about
22 nucleotides in length, non-coding endogenous RNAmolecules
that act to inhibit protein expression by partially hybridizing to
complementary sequences, in mainly the 3′ UTR, of target RNA
transcripts (reviewed in Doxakis, 2013). Each miR is estimated
to regulate multiple target mRNAs, and the combinatorial action
of miRs is expected to regulate the expression of hundreds of
mRNAs. They display a wide variety of expression patterns and
many are differentially expressed during development or disease
(reviewed in Wienholds and Plasterk, 2005). With respect to PD,
it has been shown that two miRs, miR-34, and miR-133, are sig-
nificantly reduced in affected brain regions relative to controls
(reviewed in Mouradian, 2012). Moreover, we and others have
reported that two additional miRs, miR-7, and miR-153, target
α-synuclein, a protein critically involved in both familial and spo-
radic pathological processes of PD (Junn et al., 2009; Doxakis,
2010). Importantly, miR-7 andmiR-153 are neuron-enriched and
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show highest levels of expression in murine midbrain (Doxakis,
2010). In addition, miR-7 levels are down-regulated in the mid-
brain of mice intraperitoneally injected with the PD neurotoxin,
MPTP (Junn et al., 2009) while miR-153 has been shown to regu-
late amyloid β precursor protein (APP) expression and its levels
are significantly reduced in Alzheimer’s disease brains (Liang
et al., 2007; Long et al., 2012). Finally, both miR-7 and miR-153
have been known to modulate intracellular signaling by target-
ing upstream components of the AKT pathway (Kefas et al., 2008;
Fang et al., 2012; Song et al., 2012; Sanchez et al., 2013; Wang
et al., 2013; Wu et al., 2013).
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a
neurotoxin that was discovered accidentally in exposed humans.
Young drug addicts developed an idiopathic parkinsonian syn-
drome after intravenous self-administration of a synthetic heroin
with this contaminant (Davis et al., 1979; Langston et al., 1983).
Significantly, most of the biochemical, neuropathological, and
clinical characteristics observed, corresponded to the cardinal
symptoms of human PD with the exemption of the formation of
Lewy bodies (Langston et al., 1983; Ballard et al., 1985). At the
molecular level, MPTP is transformed into its toxic derivative 1-
methyl-4-phenylpyridinium ion (MPP+) by the enzyme MAO-B
in astrocytes (Langston et al., 1984; Nicklas et al., 1985). Today,
MPTP and MPP+ represent the most relevant and frequently
used parkinsonian toxins for animal and in culture PD models,
respectively. A number of studies have, thus far, indicated that
inhibition of complex I of the mitochondria electron transport
chain, elevation of oxidative stress, activation of pro-apoptotic
ERK-1/2 and p38 MAPK and suppression of pro-survival AKT
and mTOR signaling pathways contribute to MPP+-induced cell
death (Mizuno et al., 1987; Deguil et al., 2007; Karunakaran et al.,
2008; Cui et al., 2011).
Based on the above, our current study was undertaken to eval-
uate the ability of miR-7 and miR-153 to prevent MPP+-induced
toxicity in neurons and delineate the underlying mechanism. Our
results demonstrate that miR-7 and miR-153 could protect cor-
tical neurons against MPP+-induced death by preserving the
activation of the downstream master integrating signaling path-
way of mTOR. We argue that these findings may have important
therapeutic preclinical applications for PD.
MATERIALS AND METHODS
ETHICS STATEMENT
All rodent tissues were obtained in accordance with European
Union (2003/65/CE) guidelines regarding the use of labora-
tory animals. Experimental protocols were approved by the
Institutional Animal Care and Use Committee of BRFAA and the
Veterinary Services of Attica prefecture (K/2134).
ANTIBODIES
The rabbit polyclonal antibodies phospho-S6 ribosomal protein
(Ser240/244 CST#2215), phospho-eEF2k (Ser366, CST#3691),
phospho-p70 S6 kinase (Thr389, CST#9234), phospho-AKT
(Ser473, CST#9271), phospho-ERK1/2 (Thr202/Tyr204, CST#
9101), phospho-p38 (Thr180/Tyr182, CST#4511), phospho-
SAPK/JNK (Thr183/Tyr185, CST#4668), phospho-GSK3β (Ser9,
CST#), phospho-Mapkapk2 (Thr334, CST#3007), S6 ribosomal
protein (CST#2217), p70 S6 kinase (CST#9202), AKT (CST#
9272), ERK1/2 (CST#9102), p38 (CST#9212), SAPK/JNK (CST#
92588), and cleaved caspase-3 (Asp175, CST#9664) were pur-
chased from Cell Signaling Technologies (Beverly, MA, USA).
The mouse monoclonal IgG antibodies against BAX (sc-493) and
BCL-2 (sc-7382) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). The anti-GAPDH (GT239) mon-
oclonal antibody was purchased from Genetex (Irvine, CA,
USA). The mouse (CST#7076) and rabbit (CST#7074) HRP-
conjugated secondary antibodies were from Cell Signaling
Technologies.
GENERATION OF DNA CONSTRUCTS
The construction of pcDNA6.2-GW/EmGFP- scramble/pri-miR-
7/pri-miR-153 and pri-miR-7/153 plasmids has been described
previously (Doxakis, 2010). The entry plasmids pENTR/EmGFP-
scramble/pri-miR-7/pri-miR-153 and pri-miR-7/153 were con-
structed by inserting the EmGFP-pri-miR cassettes from the
pcDNA6.2-GW/EmGFP-pri-miR plasmids into the XhoI/NotI
sites of the pENTRGateway plasmid (Life Technologies, Carlsbad,
CA, USA). Using LR clonase II enzyme (Life Technologies) the
EmGFP-pri-miR cassettes were, subsequently, transferred by LR
recombination from the pENTR plasmid into the pAd5 destina-
tion adenoviral vector (Life Technologies). All pAd5/EmGFP-pri-
miR vectors were verified by sequencing before use.
ADENOVIRAL PRODUCTION
pAd5/EmGFP-pri-miR vectors were digested with the PacI
enzyme, to lineralize DNA, before transfecting into HEK293A
producer cell line in 12-well plates by using Lipofectamine 2000
according to the manufacturer’s instructions (Life Technologies).
Two days later, cells were trypsinized and transferred onto 10 cm
dishes. Culture media were replaced with fresh every 2–3 days
until visible regions of cytopathic effect were observed (typ-
ically 5–8 days post-transfection). Adenovirus-containing cells
and media were harvested when approximately 50% of cells were
detached from dish. Crude lysates were prepared by 3 freeze/thaw
cycles followed by centrifugation at 3000 rpm for 15min. To
amplify viral stock, 1% of crude adenoviral stocks were used to
infect freshly-plated HEK293A cells. Infections were allowed to
proceed until 80–90% of the cells have rounded up and were
floating (typically 2 days later). High-titer viral stocks were, once
again, prepared by 3 freeze/thaw cycles followed by centrifuga-
tion at 3000 rpm for 15min. Adenoviral titers were determined
by standard viral plaque assays. Titers were approximately 5 × 108
infectious units per ml.
NEURON CULTURE AND TRANSDUCTION
Dissociated, embryonic day 16 murine cortical neurons (>95%
pure, 9 × 105 cells/ml), were grown in Neurobasal/DMEM 1:1
medium (Life Technologies) with 0.5 × B-27 supplement (Life
Technologies), 5% heat-inactivated horse serum and Glutamax
(Life Technologies) in poly-L-lysine (SIGMA, St-Louis, USA)
coated culture plates in the absence of trophic factors (Doxakis
et al., 2004). Neurons were transduced by adenoviruses at multi-
plicity of infection (MOI) 40 at 6–7 days after plating and lysed
48 h post-transduction.
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PHARMACOLOGICAL TREATMENTS
MPP+ (SIGMA) and rapamycin (SIGMA) were dissolved at the
stock concentration of 100mM in distilled water and tissue cul-
ture grade dimethylsulfoxide (DMSO, Applichem, Darmstadt,
Germany), respectively. All experiments were initiated at day 7
or 8 after plating when all of the neurons had developed extensive
neurite outgrowths. In the case of transduced neurons all phar-
macological treatments were performed 24 h post-transduction.
In MPP+ experiments, neurons were treated with 5–50μM
MPP+ for 24 h before analysis while in mTOR experiments, neu-
rons were treated with 20 or 50 nM rapamycin for either 1 h
(for signal transduction analysis) or 24 h (for cell viability anal-
ysis). When neuronal cultures were co-treated with MPP+ and
rapamycin, the later compound was added 1 h earlier.
METHYL THIAZOL TETRAZOLIUM (MTT) ASSAY
MTT assay, a measure of mitochondrial dehydrogenase activity
in live cells, was performed in neurons cultured in 96-well poly-
L-lysine coated plates. Once the different treatments have been
completed, 10μl of MTT (Applichem) solution in PBS (5mg/ml)
was added to each well and the plate was placed back to incuba-
tor for a further 1.5 h. The MTT formazan precipitants formed
by live cells were, subsequently, dissolved in 150μl DMSO and
the absorbance was measured at 570 nm by an ELISA microplate
reader (ELx800, Bio-Tek Instruments, Winooski, VT, USA).
IMMUNOBLOTTING
Immunoblotting was used to assay the protein levels of various
intracellular signaling components in 8–9 days old cultures of
cortical neurons transduced and/or treated with pharmacological
compounds. Neurons were harvested in a lysis buffer containing
25mMTris pH 7.5, 150mMNaCl, 1mMEDTA, 1%Triton X-100,
phosphatase (PhosSTOP®, Roche Applied Sciences, Penzberg,
Bavaria, Germany) and protease (Complete®, Roche Applied
Sciences) inhibitor cocktails. Cellular protein content was deter-
mined by the Bradford assay (Biorad, Hercules, CA, USA). Equal
amounts of cell extracts were supplemented with 6x SDS sam-
ple buffer (375mM Tris pH6.8, 10% SDS, 50% glycerol, 10%
β-mercaptoethanol, 0.03% bromophenol blue), boiled for 5min
and subjected to SDS-PAGE under reducing conditions on 10 or
12% polyacrylamide gels, depending on themolecular mass of the
proteins under examination. After electrophoresis, the resolved
proteins were transferred to Protran® nitrocellulose membrane
(Whatman, Kent, UK) by electroblotting. Subsequently mem-
branes were saturated for 1 h at room temperature in 5% non-fat
milk/0.1% Tween-20 in TBS and incubated at overnight at 4◦C in
5% non-fat milk/TBS containing the primary antibody. All pri-
mary antibodies were used at 1:1000 dilution as recommended
by vendors. The following day, membranes were washed in TBS,
incubated for 1 h at room temperature in 5% non-fat milk/TBS
containing the appropriate HRP-conjugated secondary antibody,
washed in TBS and finally developed using the Western Lighting
Plus ECL reagents (PerkinElmer, Waltham, MA, USA) according
to the manufacturer’s instructions. To ensure equal loading, fol-
lowing film exposure membranes were washed in 0.1% Tween-20
in TBS (TBST), incubated for 30min at 50◦C in stripping buffer
(2% SDS, 0.8% mercaptoethanol, 62.5mM Tris-HCl pH6.8),
extensively washed in TBST and after saturation reprobed with
the appropriate primary antibodies. Each sample was tested in
duplicate and samples obtained from three or four independent
experiments were used for analysis. Densitometric analysis of
immunoblotting images was performed using the image analysis
software Image J, NIH USA.
STATISTICAL ANALYSIS
Mean values were derived from three to five independent experi-
ments performed in duplicate. The effect of treatment on the dif-
ferent parameters examined was assessed using One-Way ANOVA
with treatment as independent factor. Bonferroni post-hoc analy-
sis was performed where applicable. Significance was defined as
p < 0.05. All statistical analyses were performed using the SPSS
software (Release 10.0.1, SPSS, Chicago, IL, USA).
RESULTS
MPP+ TREATMENT INDUCED APOPTOSIS IN CORTICAL NEURONS IN A
CONCENTRATION-DEPENDENT MANNER, ACCOMPANIED BY
ALTERATIONS IN ALL MAJOR INTRACELLULAR SIGNALING CASCADES
In order to study the mechanism of MPP+-induced cell death in
our experimental system, 7 days old primary cultures of corti-
cal neurons were treated with various concentrations of MPP+
for 24 h. Neuronal viability was, initially, monitored using the
MTT assay. As shown in Figure 1A, a 24-h treatment with MPP+
induced cytotoxicity in a concentration-dependent manner; loss
of viability extended from 7 to 67% with MPP+ concentrations
ranging between 5 and 50μM. Statistical analysis revealed a sig-
nificant effect of MPP+ treatment [F(5, 35) = 45.662, P < 0.001
and post-hoc] at 10, 20, 30, and 50μM, but not 5μM, of MPP+.
Subsequently, the protein levels of the apoptotic-related factors
BCL-2, BAX and cleaved caspase-3 were assayed by immunoblot
analysis. Consistent with the loss in cell viability, levels of BCL-
2, a major pro-survival protein, were significantly reduced by 20,
30, and 48% in cortical neurons treated for 24 h with 10, 20,
and 30μM of MPP+, respectively [F(3, 11) = 23.699, P < 0.001
and post-hoc; Figure 1B]. In contrast, a dose-dependent increase
was observed in protein levels of cleaved caspase-3, an important
effector caspase. More specifically, compared to untreated con-
trols, primary cortical neurons treated for 24 h with 10, 20 and
30μM of MPP+ displayed a significant 3.2-, 6.5-, and 11.3-fold
increase of cleaved caspase-3 levels, respectively [F(3, 11) =
52.150, P < 0.001 and post-hoc; Figure 1C]. In our experimen-
tal system, the levels of BAX, a major pro-apoptotic factor,
were not significantly altered (data not shown). Collectively,
these data indicate that MPP+ induced a dose-dependent
neuronal death that displayed apoptotic features.
It is well established that cell apoptosis and survival are regu-
lated by intracellular signaling cascades; thus, activation by phos-
phorylation of the major signaling effectors was next examined
in the same experimental system. As shown in Figures 2A,B, and
consistent with previous studies (Junyent et al., 2010; Cui et al.,
2011; Hashimoto et al., 2012), the levels of phosphorylated AKT, a
major pro-survival kinase, were significantly reduced by∼30% in
cortical neurons treated with 20 and 30μM of MPP+ [F(3, 15) =
10.932, P = 0.001 and post-hoc], whereas levels of phosphory-
lated p38 MAPK, a major pro-apoptotic kinase, were significantly
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FIGURE 1 | MPP+ induced neurotoxicity in cortical neurons. Seven-day
primary cortical neurons were treated with various concentrations of
MPP+ for 24 h. (A) Cell viability following dose-dependent treatments was
assayed by measuring MTT reduction by live neurons. Note that a
significant reduction in neuronal viability was observed upon treatment
with 10, 20, 30, and 50μM, but not 5μM, of MPP+. (B,C) Equal amounts
of total protein from lysates of cortical neurons cultured for 24 h in the
presence of 10, 20, and 30μM MPP+ were analyzed on 12% SDS-PAGE
and immunoblotted with antibodies specific for BCL-2 (B) and cleaved
caspase-3 (C). To ensure equal loading, membranes were re-probed
against GAPDH. Note that compared to untreated controls, primary cortical
neurons treated for 24 h with MPP+ displayed a dose-dependent decrease
of BCL-2 protein levels, as well as a dose-dependent increase of cleaved
caspase-3 protein levels. Quantification of the results in (B,C) was
performed by scanning densitometry. Bars in all the presented graphs
depict mean ± s.e.m. ∗∗∗P ≤ 0.001.
FIGURE 2 | Cortical neurons treated with MPP+ displayed alterations
in all major intracellular signaling cascades. Seven-day primary cortical
neurons were treated with 10, 20, and 30μM MPP+ for 24 h. Equal
amounts of total protein from lysates of cortical neurons were analyzed on
10% SDS-PAGE and immunoblotted with antibodies specific for
phosphorylated forms of AKT (A), p38 MAPK (B), ERK1/2 (C), JNK/SAPK
(D), p70S6K (E), as well as for the phosphorylated forms of p70S6K
substrate S6RP (F). To ensure equal loading membranes were re-probed
against AKT, p38 MAPK, ERK1/2, JNK/SAPK, p70S6K, and S6RP,
respectively. Quantification of the results was performed by scanning
densitometry. Bars in the graph depict mean ± s.e.m. Note that
MPP+-treatment changed the phosphorylation status of all the major
signaling kinases examined in a concentration dependent manner.
∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001.
increased at all MPP+ concentrations applied [F(3, 15) = 5.996,
P = 0.01 and post-hoc]. Similar results were observed in the lev-
els of phosphorylated GSK-3β and MAPKAPK-2, downstream
effectors of AKT and p38 MAPK, respectively (data not shown).
Moreover, cortical neurons treated for 24 h with 20 or 30μM,
but not 10μM, of MPP+ displayed significant alterations in the
levels of phosphorylated ERK1/2, a dubious MAPK, as well as
of phosphorylated stress-induced kinases SAPK/JNK; levels of
phosphorylated ERK1/2 were up-regulated by 110 and 170%
[F(3, 11) = 11.806, P < 0.01 and post-hoc; Figure 2C] and those
of phosphorylated SAPK/JNK were down-regulated by 38 and
60% [F(3, 15) = 33.699, P < 0.001 and post-hoc; Figure 2D] at 20
and 30μM of MPP+, respectively. Finally, as shown in Figure 2E,
in our experimental system MPP+ treatment also significantly
reduced the phosphorylation status of the mTOR effector p70S6
kinase, even when applied at 10μM; this reduction extended from
27% at 10μM to 72% at 30μM of MPP+ [F(3, 15) = 20.701,
P < 0.001 and post-hoc]. Similar reductions were also observed
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in the levels of activated S6RP [F(3, 15) = 60.445, P < 0.001 and
post-hoc; Figure 2F] and of activated eEF2K [F(3, 11) = 18.310,
P = 0.001 and post-hoc; data not shown], two p70S6K sub-
strates which mediate translation and cell growth (reviewed in
Laplante and Sabatini, 2013). It is therefore evident that in cor-
tical neurons, a 24-h treatment with MPP+ leads to changes in
the phosphorylation status of all major signaling kinases, in a
concentration-dependent manner.
OVER-EXPRESSION OF miR-7 AND/OR miR-153 IN CORTICAL NEURONS
ATTENUATED MPP+-INDUCED NEUROTOXICITY
It has been shown that miR-7 and miR-153 target α-synuclein, a
protein critically involved in PD pathogenesis (Junn et al., 2009;
Doxakis, 2010) andmost importantly that miR-7 levels are down-
regulated in the midbrain of mice intraperitoneally injected with
the PD neurotoxin, MPTP (Junn et al., 2009). Therefore, in order
to evaluate possible neuroprotective effects of miR-7 and/or miR-
153 againstMPP+ insult, 6- to 7-day old primary cortical neurons
were transduced with adenoviral particles expressing scramble
miR, miR-7, miR-153, or both of these two miRs, miR-7/153.
It should be noted that irrespective of the adenoviral particles
used, overall adenoviral infection of primary cortical neurons
affected cell viability, whereas adenoviral over-expression of miR-
7 and/ormiR-153 had no effect on neuronal viability compared to
adenoviral expression of scramble miR (Supplemental Figure 1).
Thus, in order to avoid any confounding effects due to the infec-
tion per se, all subsequent comparisons were performed between
primary neurons transduced with adenoviral particles expressing
a scramble miR and primary neurons transduced with adenovi-
ral particles expressing the miR(s) of interest. Twenty four hours
post-transduction, cortical neurons were exposed to MPP+ con-
centrations ranging between 5 and 50μM and left in culture for
additional 24 h. Neuronal viability was then monitored by the
MTT assay. As shown in Figure 3A and similar to uninfected
neuronal cultures (see Supplemental Figure 2) in the scramble
miR transduced cultures loss of viability extended from 10 to
62% with MPP+ concentrations ranging between 5 and 50μM.
Statistical analysis revealed a significant effect of MPP+ treatment
[F(5, 29) = 48.968, P < 0.001 and post-hoc] at 10, 20, 30, and
50μM, but not 5μM, of MPP+. In contrast, neuronal viability
in miR-7 or miR-153 transduced cultures was not impaired when
treated with 5, 10, or 20μM of MPP+ and it was only reduced
at the higher concentrations applied i.e., 30 and 50μM [miR-
7: F(5, 29) = 32.948, P < 0.001 and post-hoc; miR-153: F(5, 29) =
24.816, P < 0.001 and post-hoc; Figure 3A]. Interestingly, in neu-
ronal cultures transduced with adenoviral particles expressing
both miR-7/153 neuronal viability was only impaired upon 24-
h treatment with 50μM MPP+ [F(5, 29) = 11.803, P < 0.001
and post-hoc; Figure 3A], Nevertheless, even at the highest con-
centration applied, compared to scramble miR transduced con-
trol cultures, neuronal cultures transduced with both miR-7/153
displayed an approximately 2-fold increase in neuronal viabil-
ity upon 24-h treatment with 50μM MPP+ [F(3, 19) = 11.444,
P < 0.001 and post-hoc; Figure 3A].
Finally, as depicted in Figures 3B,C, compared to scramble
miR transduced untreated controls, only scramble-transduced
cortical neurons displayed a significant decrease in the levels of
anti-apoptotic BCL-2 [F(4, 14) = 4.567, P < 0.05 and post-hoc],
accompanied by a significant increase of cleaved caspase-3 levels
[F(4, 14) = 10.438, P = 0.001 and post-hoc], upon 24-h treatment
with 10μM of MPP+. No such changes were observed among
scramble-transduced untreated controls and MPP+-treated neu-
ronal cultures transduced with miR-7, miR-153, or miR-7/153
adenoviruses, suggesting that over-expression of miR-7 and miR-
153 in cortical neurons attenuated both the MPP+-induced
down-regulation of pro-survival BCL-2 protein and activation of
the pro-apoptotic caspase-3.
miR-7 AND miR-153 ACTIVATED p70S6K SIGNALING CASCADE IN
PRIMARY CORTICAL NEURONS AND ATTENUATED THE EFFECTS OF
RAPAMYCIN ON mTOR SIGNALING AND CELL VIABILITY
Given a number of studies that show that miR-7 and miR-153
modulate intracellular signaling (Kefas et al., 2008; Fang et al.,
2012; Song et al., 2012; Sanchez et al., 2013; Wang et al., 2013, Wu
FIGURE 3 | Neuroprotective effects of miR-7 and miR-153 against
MPP+-toxicity. Six to seven days old primary cortical neurons were
transduced with adenoviral particles expressing scramble miR, miR-7,
miR-153, or both miR-7/153. After 24 h, transduced neurons were exposed
for additional 24 h to various concentrations of MPP+. (A) Neuronal viability
following MPP+-treatment was monitored by the MTT assay. Note that
over-expression of miR-7 and/or miR-153 attenuated MPP+-induced cell
death. (B,C) Equal amounts of total protein from lysates of transduced
cortical neurons cultured for 24 h in the presence of 10μM MPP+ were
analyzed on 12% SDS-PAGE and immunoblotted with antibodies specific for
BCL-2 (B) and cleaved caspase-3 (C). To ensure equal loading membranes
were re-probed against GAPDH. Quantification of the results was performed
by scanning densitometry. Note that compared to scramble-transduced
untreated controls, only scramble-transduced cortical neurons displayed
significant changes in BCL-2 and cleaved caspase-3 protein levels. Bars in all
the depicted graphs correspond to mean ± s.e.m. ∗P ≤ 0.05, ∗∗∗P ≤ 0.001.
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et al., 2013) in non-neuronal cells, we next investigated whether
these miRs affect the activation of the major intracellular signal-
ing cascades in neurons. Therefore, 6–7 days old primary cortical
neurons were transduced with adenoviral particles expressing
scramble miR, miR-7, or miR-153, and the activation of signaling
kinases was assessed 48 h later by immunoblotting. As depicted in
Figure 4A, overexpression of miR-7 or miR-153 in cortical neu-
rons did not affect the phosphorylation status of pro-survival
kinase AKT or of the pro-apoptotic p38MAPK and similar results
were also observed in the levels of phosphorylated GSK-3β and
MAPKAPK-2, downstream effectors of AKT and p38 MAPK,
respectively (data not shown). Finally, no significant change was
either observed in the levels of phosphorylated ERK1/2 or those
of activated stress-induced kinases SAPK/JNK (Figure 4A).
Markedly, in the same experimental system, both miR-7 and
miR-153 appeared to induce p70S6 kinase signaling downstream
FIGURE 4 | miR-7 and miR-153 activated p70S6K signaling cascade in
cortical neurons. Six to seven days old primary cortical neurons were
transduced with adenoviral particles expressing scramble miR, miR-7, or
miR-153 and were lysed 48 h post-transduction. (A) Equal amounts of total
protein from lysates of cortical neurons were analyzed on 10% SDS-PAGE
and immunoblotted with antibodies specific for phosphorylated forms of
AKT, p38 MAPK, ERK1/2 SAPK/JNK. To ensure equal loading membranes
were re-probed against AKT, p38 MAPK, ERK1/2, and SAPK/JNK,
respectively. (B,C) Equal amounts of total protein from lysates of cortical
neurons were analyzed on 10% SDS-PAGE and immunoblotted with
antibodies specific for phosphorylated forms of p70S6K (B) as well as for
the phosphorylated forms of p70S6K substrate, S6RP (C). To ensure equal
loading, membranes were re-probed against p70S6K and S6RP,
respectively. Quantification of the results was performed by scanning
densitometry. Bars in the graph depict mean ± s.e.m. Note that compared
to scramble-transduced controls, primary cortical neurons transduced with
miR-7 or miR-153 expressing adenoviruses displayed a significant increase
only in the levels of phosphorylated forms of p70S6K and S6RP. ∗∗P ≤ 0.01,
∗∗∗P ≤ 0.001.
of the mTOR signaling cascade. More specifically, levels of
phosphorylated p70S6K were significantly up-regulated by
45 and 52% in cortical neurons transduced with adenoviral
particles expressing miR-7 and miR-153, respectively [ANOVA:
F(2, 14) = 8.056, P < 0.01 and post-hoc; Figure 4B]. Consistent
with the above, phosphorylation of p70S6K substrates S6RP
and eEF2K was also significantly increased; levels of phos-
phorylated S6RP were up-regulated by 89 and 83% [ANOVA:
F(2, 11) = 20.084, P < 0.001 and post-hoc; Figure 4C], whereas
levels of phosphorylated eEF2K were increased by 36 and 62%
[ANOVA: F(2, 11) = 7.475, P < 0.05 and post-hoc; data not
shown] upon overexpression of miR-7 and miR-153, respectively.
The latter mTOR downstream activation by miR-7 or miR-153
is unlikely to be attributed to an unspecific scramble miR effect,
since transduction with adenoviral particles expressing scramble
miR appeared to have no effect on the phosphorylation of
p70S6K and of its substrate S6RP compared to transduced empty
control neurons (Supplemental Figure 3). Taken together the
latter observations suggest that miR-7 and miR-153 may activate
the mTOR signaling cascade.
To further explore the latter hypothesis, 6–7 days old primary
cortical neurons were again transduced with adenoviral particles
expressing scramble miR, miR-7, or miR-153 and left in cul-
ture for additional 48 h. One hour before harvest, cultures were
supplemented with 20 nM rapamycin, a potent mTORC1 (and
mTORC2 at higher doses and long-term treatment) inhibitor
(Sarbassov et al., 2006; Rosner and Hengstschlager, 2008; Chen
et al., 2010) and levels of phosphorylated mTORC1 effector
p70S6K and its phosphorylated substrates S6RP and eEF2K
were determined. As shown in Figure 5A, irrespective of the
adenovirus used, 1-h rapamycin treatment resulted to a signifi-
cant decrease in the levels of phosphorylated p70S6K [ANOVA:
F(3, 11) = 36.857, P < 0.001 and post-hoc]; nevertheless, pri-
mary cortical neurons transduced with miR-7 or miR-153 sus-
tained phosphorylated p70S6K levels at more than 2-fold higher
than scramble miR-transduced controls (post-hoc, P < 0.01).
Consistently, overexpression of miR-7 and miR-153 attenuated
the effect of rapamycin on the phosphorylation of S6RP [ANOVA:
F(3, 11) = 71.638, P < 0.001 and post-hoc; Figure 5B], and of
eEF2K [ANOVA: F(3, 11) = 65.623, P < 0.001 and post-hoc;
Figure 5B], More specifically, compared to scramble-transduced
rapamycin-treated controls, primary cortical neurons transduced
with miR-7 or miR-153 and treated with rapamycin displayed
significantly increased levels of phosphorylated S6RP (4.7- and
5.4-fold increase in the case of miR-7, miR-153 overexpression,
respectively; post-hoc, P < 0.001), as well as of phosphorylated
eEF2K (by 90% for miR-7 and 65% for miR-153, post-hoc, P <
0.001). It appears, therefore, that miR-7 and miR-153 may act as
“activators” of mTOR signaling pathway.
Given that mTOR signaling pathway is a downstream regu-
lator of neuronal survival (see also Supplemental Figure 4), we
next wanted to examine whether overexpression of miR-7 and/or
miR-153 is able to interfere with the effect of mTOR signaling
inhibition on cell survival. In order to address this, 6–7 days
old primary cortical neurons were transduced with adenoviral
particles expressing scramble miR, miR-7, or miR-153, supple-
mented with 20 nM rapamycin 24 h post-transduction, and left in
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FIGURE 5 | Overexpression of miR-7 or miR-153 attenuated the effects of
rapamycin in cortical neurons. (A,B) Six to seven days old primary cortical
neurons were transduced with adenoviral particles expressing scramble miR,
miR-7, or miR-153 and left in culture for additional 48 h. One hour before
harvest, cultures were supplemented with 20 nM rapamycin. Equal amounts
of total protein from lysates of cortical neurons were analyzed on 10%
SDS-PAGE and immunoblotted with antibodies specific for phosphorylated
forms of p70S6K, S6RP, and eEF2K. To ensure equal loading, membranes
were re-probed against GAPDH. Quantification of the results was performed
by scanning densitometry. Note that overexpression of miR-7, as well as that
of miR-153 attenuated the effect of rapamycin on the phosphorylation of all
proteins examined. (C) Six to seven days old primary cortical neurons were
transduced with the same adenoviral particles and after 24 h were exposed to
20 nM of rapamycin for an additional of 24 h. Neuronal viability following 24-h
treatment with rapamycin was monitored by the MTT assay. Note that
overexpression of miR-7 and/or miR-153 attenuated rapamycin-induced cell
death. Bars in all the presented graphs depict mean ± s.e.m. ∗∗P ≤ 0.01,
∗∗∗P ≤ 0.001.
culture for an additional 24 h. Neuronal viability was monitored
using the MTT assay. As depicted in Figure 5C, a 24-h treatment
with rapamycin reduced significantly the viability of scramble-
transduced neuronal cultures to 77% [ANOVA: F(3, 11) = 32.804,
P < 0.001 and post-hoc], a reduction that was comparable to
the one observed in untransduced cortical neuronal cultures
(Supplemental Figure 4). In contrast, viability ofmiR-7-, ormiR-
153- transduced neuronal cultures was not significantly impaired,
providing further support that these two miRs sustain mTOR
signaling in neurons.
OVEREXPRESSION OF miR-7 AND/OR miR-153 IN CORTICAL NEURONS
ATTENUATED MPP+-INDUCED NEUROTOXICITY VIA UPREGULATION
OF mTOR PATHWAY
Our results so far suggest that miR-7 and miR-153 are able to
induce rapamycin-sensitive mTOR downstream signaling, which
appeared significantly impaired in cortical neurons upon MPP+
treatment. Therefore, in order to evaluate whether miR-7 and/or
miR-153 exert their neuroprotective effect through upregulation
ofmTOR signaling pathway, 6- to 7- day old primary cortical neu-
rons were again transduced with adenoviral particles expressing
scramble miR, miR-7, or miR-153, as well as with an adenovi-
ral construct expressing both of these two miRs. Twenty four
hours post-transduction, cortical neurons were exposed to 10μM
of MPP+ and the activation of p70S6K and its substrates was
assessed 24 h later by immunoblotting. As shown in Figures 6A,B,
compared to scramble-transduced untreated controls, 24-h treat-
ment with 10μM of MPP+ induced a significant decrease in the
levels of phosphorylated p70S6K [F(4, 14) = 5.072, P < 0.05 and
post-hoc] and of its phosphorylated substrate S6RP [F(4, 14) =
5.241, P < 0.05 and post-hoc] in only the scramble-transduced
cortical neurons; overexpression of miR-7 or miR-153 attenuated
the MPP+-induced reduction in the activation of p70S6K and its
downstream targets, while overexpression of both miRs restored
their phosphorylation status to that of scramble-transduced
untreated controls. To further explore the possibility that sus-
tainedmTOR downstream signaling activation underlies the neu-
roprotective effects of miR-7 and miR-153, 20 nM of rapamycin
was co-administered with 10μM MPP+ in these neuronal cul-
tures. As shown in Figure 6C, in scramble miR-transduced cul-
tures all treatments lead to a significant reduction in neuronal
viability [F(3, 11) = 25.244, P < 0.001 and post-hoc]. In contrast,
in miR-7, miR-153, or miR-7/153 -transduced cultures, neu-
ronal viability was significantly impaired only when MPP+ was
co-administered with rapamycin [miR-7: F(3, 11) = 41.253, P <
0.001 and post-hoc; miR-153: F(3, 11) = 14.061, P = 0.001 and
post-hoc, miR-7/153: F(3, 11) = 26.653, P < 0.001 see Figure 6C].
Taken together the above results suggest that miR-7 and/or miR-
153 induced activation of mTOR pathway largely mediates their
neuroprotective effect against MPP+ toxicity in cortical neurons.
Finally, in order to explore whether miR-7 and/or miR-153
interfere with MPP+-induced changes in other than mTOR
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FIGURE 6 | miR-7 and/or miR-153 attenuated MPP+-induced
neurotoxicity via upregulation of rapamycin sensitive mTOR pathway.
(A,B) Six to seven days old primary cortical neurons were transduced with
adenoviral particles expressing scramble miR, miR-7, miR-153, or both
miR-7/153. After 24 h, transduced neurons were exposed for additional
24 h to 10μM of MPP+. Equal amounts of total protein from lysates of
transduced cortical neurons cultured for 24 h in the presence of 10μM
MPP+ were analyzed on 10% SDS-PAGE and immunoblotted with
antibodies specific for phosphorylated forms of p70S6K (A) and S6RP (B).
To ensure equal loading membranes were re-probed against p70S6K and
S6RP, respectively. Note that overexpression of miR-7 and/or miR-153
attenuated the effect of MPP+ on the phosphorylation of all proteins
examined. Quantification of the results was performed by scanning
densitometry. (C) Six to seven days old cultures of primary cortical
neurons were transduced as described above, and 24 h later were exposed
to 20 nM of rapamycin, 10μM of MPP+, or both. Neuronal viability was
monitored 24 h post-exposure by the MTT assay. Note that in the
presence of rapamycin, overexpression of miR-7 and/or miR-153 failed to
protect cortical neurons against MPP+-induced cell death. Bars in all
presented graphs depict mean ± s.e.m. ∗P < 0.05, ∗∗∗P ≤ 0.001.
intracellular signaling cascades, the phosphorylation status of
other major signaling effectors was examined in cortical neurons
transduced with scramble miR, miR-7, miR-153, or miR-7/153
adenoviruses and treated for 24 h with 10μM MPP+. As shown
in Figure 7A, inMPP+-treated cortical neurons overexpression of
both miR-7/153, but not that of miR-7 or miR-153 alone, attenu-
ated theMPP+-induced reduction in the levels of phosphorylated
AKT [F(4, 24) = 12.314, P = 0.01 and post-hoc]. Interestingly,
miR-153, but not miR-7 or miR-7/153, attenuated the MPP+-
induced activation of pro-apoptotic p38 MAPK [F(4, 24) =
12.978, P = 0.01 and post-hoc; Figure 7B]. Finally, overexpres-
sion of miR-7 and/or miR-153 had no significant effect on the
phosphorylation status of ERK1/2 (Figure 7C), but resulted in
a significant increase of phosphorylated SAPK/JNK levels to
above control levels [F(4, 24) = 15.894, P < 0.001 and post-hoc;
Figure 7D]. It, therefore, appears that miR-7 and/or miR-153
alter the intracellular response of cortical neurons toMPP+ insult
and thus interfere with MPP+-induced neurotoxicity.
DISCUSSION
The mechanisms underlying chronic neurodegeneration in PD
remain obscure. An emerging hypothesis is that neuronal systems
deteriorate and eventually degenerate due to failure of intrinsic
cellular pathways that mediate neuronal homeostasis. This fail-
ure maybe due to lack of external neurotrophic support or to
mutations in intrinsic factors such as the PARK genes that modify
intracellular signaling (reviewed inWang et al., 2012). Thus, far, a
great number of studies have indicated that neurotrophic factors
or herbal extracts protect neurons from PD insults by enhancing
pro-survival and/or decreasing pro-apoptotic signaling pathways
(Nakaso et al., 2008; Wang et al., 2010; Cui et al., 2011; Zhang
et al., 2011; Bao et al., 2012; Hashimoto et al., 2012). In addition,
manipulation of specific intracellular signaling cascades by either
overexpressing or inhibiting signaling protein kinases has revealed
that they modulate most PD neurotoxin effects (Malagelada et al.,
2006; Zhu et al., 2007, 2012; Nakaso et al., 2008; Cui et al., 2011;
Bao et al., 2012; Piao et al., 2012). Most importantly, these find-
ings phenocopy data from the analysis of human postmortem PD
brains that show decreased phosphorylation of pro-survival and
enhanced activation of pro-apoptotic pathways (Zhu et al., 2002,
2003; Malagelada et al., 2006; Timmons et al., 2009; Reinhardt
et al., 2013).
Previous work from our group has shown that mir-7 and mir-
153 significantly regulate the expression of α-synuclein, a protein
encoded by the gene SNCA that belongs to the PARK gene family
(Doxakis, 2010). A-synuclein plays a seminal role in neurodegen-
eration and has been shown, among others, to affect signaling
by modulating neurotrophin BDNF expression and AKT activ-
ity (Yuan et al., 2010; Chung et al., 2011). Based on the intrinsic
property of miRs to regulate the expression of multiple proteins
and possibly the activation of signaling cascades, in the present
study we wished to investigate if miR-7 and miR-153 protect
neurons exposed to PD insults via altering intracellular signal-
ing. Thus, we evaluated whether overexpression of mir-7 and/or
mir-153 could prevent MPP+-induced toxicity in cortical neu-
rons. Cortical neurons were selected because they are directly
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FIGURE 7 | Effect of miR-7 and/or mir-153 overexpression on AKT, p38,
ERK-1/2, and SAPK/JNK signaling in MPP+-treated cortical neurons.
Six to seven days old primary cortical neurons were transduced with
adenoviral particles expressing scramble miR, miR-7, miR-153, or both
miR-7/153. After 24 h, transduced neurons were exposed for additional 24 h
to 10μM of MPP+. Equal amounts of total protein from lysates of
transduced cortical neurons cultured for 24 h in the presence of 10μM
MPP+ were analyzed on 10% SDS-PAGE and immunoblotted with
antibodies specific for phosphorylated forms of AKT (A), p38 MAPK (B),
ERK1/2 (C), and SAPK/JNK (D). To ensure equal loading membranes were
re-probed against AKT, p38 MAPK, ERK1/2, and SAPK/JNK, respectively.
Quantification of the results was performed by scanning densitometry. Bars
in all the presented graphs depict mean ± s.e.m. Note that miR-7, miR-153,
or miR-7/153 altered in an opposite way MPP+-induced changes in
intracellular signaling cascades. ∗∗∗P < 0.001.
affected in PD by showing progressive pathology (Trojanowski
et al., 1998; Braak et al., 2006) and they can be isolated in great
numbers relative free of glial cells. MPP+, on the other hand, is a
widely used neurotoxin that reproduces the neuronal dysfunction
of PD both in vivo and in different cell systems in vitro. MPP+
enters cells through the dopamine re-uptake system, present in
dopaminergic neurons; however, at higher concentrations it can
enter all cell types by passive diffusion (Reinhard et al., 1990)
and/or by the extraneuronal monoamine transporter (Russ et al.,
1996). The mechanism of MPP+ toxicity in cells is rather ubiq-
uitous and involves inhibition of the mitochondrial respiratory
chain, elevation of oxidative stress and alteration of intracellular
signaling. The vulnerability of neurons to MPP+ is modified by
microglia numbers in the vicinity of neurons, neurotrophic sup-
port, glutathione, or superoxide dismutase content (antioxidant
capacity), the content of redox active molecules or elements (such
as dopamine or iron), the ratio of anti-apoptotic vs. pro-apoptotic
BCL-2 family proteins and basal levels of phosphorylated sig-
naling kinases (Lawson et al., 1990; Kim et al., 2000; Zigmond
et al., 2002; Wu et al., 2003; Zecca et al., 2004; Willis et al., 2007).
Noteworthy, modulation of intracellular signaling pathways has
been shown to mediate most of the MPP+ effects in neurons
indicating that signaling cascades are downstream of MPP+ tar-
gets and/or can reverse pro-apoptotic effects (Nakaso et al., 2008;
Wang et al., 2010; Cui et al., 2011; Bao et al., 2012; Hashimoto
et al., 2012; Piao et al., 2012).
Based on the above, we initially characterized the molecular
mechanisms underlying MPP+-induced neuronal death in corti-
cal neurons since most studies have been carried out in dividing
neuroblastoma cells and/or were limited to two or three sig-
naling pathways. Hence, the levels of apoptosis-related BCL-2
family members and the major signaling pathways, AKT, ERK-
1/2, p38, SAPK/JNK, and mTOR were determined. Consistent
with previous studies, we found that MPP+-induced neuro-
toxicity displayed apoptotic characteristics, as documented by
the reduced levels of BCL-2 and the increased levels of cleaved
caspase-3, and was accompanied by enhanced activities of the
pro-apoptotic p38 and ERK-1/2MAPK signaling pathways as well
as by reduced activation of pro-survival AKT and p70S6K kinases
(Deguil et al., 2007; Junyent et al., 2010; Cui et al., 2011; Bao et al.,
2012; Hashimoto et al., 2012; Rodriguez-Blanco et al., 2012).
Finally, contrary to most other findings (Wang et al., 2010; Zhang
et al., 2011; Hashimoto et al., 2012; Rodriguez-Blanco et al.,
2012), and with the exception of a single study (Sun and Chang,
2003), activation of the SAPK/JNK kinase was suppressed in a
dose-dependent manner by MPP+ treatment of cortical neurons.
Subsequently, the effect of miR-7 and miR-153 overexpression
in neurons was determined. We found that miR overexpression
did not, overall, alter neuronal viability or the activity of AKT,
ERK-1/2, p38, and SAPK/JNK signaling pathways. However, a
significant upregulation of mTORC1 downstream signaling was
observed by the overexpression of both miRs, as evident by
the increased levels of phosphorylated p70S6K and its down-
stream targets S6RP and eEF2K. mTOR complexes (mTORC1/2)
serve as central regulators of cell metabolism, growth and sur-
vival by integrating intracellular (energy status, oxygen, and
amino acids) and extracellular signals (growth factors) (Wu
et al., 2004; Takei et al., 2009; reviewed in Swiech et al., 2008;
Laplante and Sabatini, 2013). Mutant mTOR embryos lack telen-
cephalon and die by midgestation, an effect that is phenocopied
by the mTOR inhibitor, rapamycin, validating the importance
of this pathway in brain development (Hentges et al., 2001). In
cultured neurons, mTORC1, the best studied mTOR complex,
has been shown to regulate soma size, dendrite axonal growth,
Frontiers in Cellular Neuroscience www.frontiersin.org July 2014 | Volume 8 | Article 182 | 9
Fragkouli and Doxakis Neuroprotection by miR-7 and miR-153
dendrite development, and regeneration (Campbell and Holt,
2001; Jaworski et al., 2005; Kumar et al., 2005; Tavazoie et al.,
2005; Verma et al., 2005; Li et al., 2008; Park et al., 2008). Our
finding that the activation of mTOR downstream effectors was
significantly increased in cortical neurons over-expressing miR-7
or miR-153, suggests that these two miRs may act as “activators”
of mTOR signaling pathway. The latter hypothesis is further sup-
ported by our observations showing that overexpression of miR-7
or miR-153 in primary neurons is able to attenuate the effects of
rapamycin on both the activation of mTOR downstream effectors
and neuronal viability.
Probing the effect of miR-7 and miR-153 overexpression in
MPP+-treated neurons, we revealed that they could, either alone
or together, significantly protect neurons from cell death. We rea-
soned that this was due to enhanced mTOR signaling as this was
the only pathway that was upregulated by the overexpression of
both miRs. Consistent with the latter hypothesis, overexpression
of miR-7 and/or miR-153 attenuated the MPP+-induced reduc-
tion on the activation of p70S6K and its downstream targets,
whereas treatment of transduced neurons with rapamycin abol-
ished the pro-survival effects of miR-7 and miR-153 upon MPP+
exposure.
To further explore the modulation of intracellular signaling by
miR-7 and miR-153 overexpression in MPP+-treated neurons,
the activation of the remaining pathways was also determined.
It should be noted that compared to untransduced cortical neu-
rons, transduced primary cortical neurons used in the present
study appeared less resistant to MPP+-treatment and therefore
displayed a more robust intracellular response to the same MPP+
concentration i.e., 10μM; this is likely to be attributed to the
adenoviral transduction, given that it comprises an additional,
to that of MPP+, insult for the cortical neurons. Taking the lat-
ter observation into account, herein we found that the activity of
AKT which is known to activate mTORC1 by alleviating the inhi-
bition induced by TSC2 and PRAS40 proteins (Dan et al., 2002;
Inoki et al., 2002; Manning et al., 2002; Vander Haar et al., 2007;
Zhu et al., 2007), was not restored by either miR-7 or miR-153;
however, overexpressing both miR-7 and miR-153 significantly
relieved the suppression of AKT activation by MPP+, likely by
having overlapping or additive effects on their targets. In addi-
tion, the finding that AKT was activated at Ser473, known to be
mediated bymTORC2 complex (Sarbassov et al., 2005), may indi-
cate that mTORC2 signaling is also contributing to the survival of
neurons transduced by both miRs. p38 is a stress kinase that has
been linked to neuro-inflammation and MPP+-mediated apop-
tosis (Karunakaran et al., 2008; Thomas et al., 2008b). It should
be noted that miR-153, but not miR-7, significantly prevented the
activation of p38 by MPP+ which may have partly contributed
to its pro-survival effects in cortical neurons. Overexpressing
miR-7 andmiR-153 together alleviated the negative effect of miR-
153 on p38 phosphorylation indicating that miR-7 targets may
block mir-153 responses on p38 signaling pathway activation.
The role of ERK-1/2 activation in neuronal survival is context-
specific; some reports show positive or negative input on survival
after induction by growth factors, glutamate, or okadaic acid
(Runden et al., 1998; Bonni et al., 1999; Satoh et al., 2000; Stanciu
et al., 2000; Cui et al., 2011) while others implicate it in MPP+-
and 6-hydroxydopamine- induced mitophagy/autophagy and cell
death (Zhu et al., 2007, 2012). In the present study, neither
miR-7 nor miR-153 overexpression significantly changed ERK-
1/2 phosphorylation in the MPP+-treated neurons. SAPK/JNK
is a kinase with an indispensable role in microtubule stability in
neurons. It stimulates dendrite formation, axodendritic length,
axonal regeneration, mediates fast axonal transport, and con-
tributes to the regulation of synaptic plasticity (Bjorkblom et al.,
2005; Chen et al., 2005; Zhu et al., 2005; Tararuk et al., 2006;
Thomas et al., 2008a; Morfini et al., 2009; Barnat et al., 2010;
Podkowa et al., 2010). At the same time it has been linked to
stress-induced apoptosis in different pathological conditions as
a result of its inhibition of autophagy and the induction of pro-
apoptotic BCL-2 family members (Jia et al., 2006; Hubner et al.,
2008; Xu et al., 2011). In our cell culture system, miR-7 and miR-
153 overexpression significantly lifted SAPK/JNK activation in the
MPP+-treated neurons. Overexpression of both miRs together
did not further induce SAPK/JNK activation indicating that they
modulate a similar target group. Additional experiments will be
required to determine if the effect of miR-7 and miR-153 over-
expression on SAPK/JNK phosphorylation partly negates their
neuroprotective responses via mTOR signaling, and/or maintains
the axodendritic growth of neurons which is impaired by MPP+-
induced microtubule dysfunction (Cartelli et al., 2010) and/or
negates MPP+-induced ERK-1/2-mediated enhanced autophagy
in neurons.
Taken together, our data suggest that miR-7 and miR-153 pro-
tect neurons against MPP+-induced toxicity via upregulation of
mTOR downstream targets. In addition, we show that miR-7 and
miR-153 modulate the signaling pathways of SAPK/JNK and p38
in MPP+-treated cells, however, their effect on neuronal viability
maybe less important. Given also our previous study showing that
miR-7 and miR-153 regulate α-synuclein expression, it appears
these two miRs may prove good therapeutic candidates for the
treatment of PD. Evidence from successful medical interventions
based on miRs has already been shown in cornerstone stud-
ies to lower plasma cholesterol levels in rodents and primates
(Krutzfeldt et al., 2005; Elmen et al., 2008a,b). Currently, a large
number of miRs are studied in preclinical and clinical settings
by biotechnology companies (Lindow and Kauppinen, 2012). In
future, it will be important to characterize the effect of miR-7 and
miR-153 on neurite outgrowth and synaptogenesis and test if they
can support neurons treated with other PD neurotoxins.
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Supplemental Figure 1 | Overexpression of miR-7 or miR-153 has no effect
on neuronal viability. (A) Six to seven days old primary cortical neurons
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were left untreated or were transduced with adenoviral particles
expressing scramble miR, miR-7, miR-153, or both miR-7153 and neuronal
viability was assayed by MTT reduction 48 h later. It should be noted that
overall adenoviral infection of primary cortical neurons affected cell
viability [F(4, 19) = 2.979, ∗P = 0.05 and post-hoc]; nevertheless, no
significant difference was observed among transduced primary neurons,
i.e., those transduced with adenoviral particles expressing a scramble miR
or the miR (s) of interest. (B) Six to seven days old primary cortical
neurons were left untreated or were transduced with the same adenoviral
particles and lysed 48 h later. Equal amounts of total protein from lysates
of cortical neurons were analyzed on 12% SDS-PAGE and immunoblotted
with antibodies specific for BCL-2 and cleaved caspase-3. To ensure equal
loading membranes were re-probed against GAPDH. Compared to
scramble-transduced controls, primary cortical neurons transduced with
miR-7, miR-153, or miR-7/153 displayed no significant change on either
BCL-2 or cleaved caspase-3 protein levels; it should be noted that a
statistically insignificant increase in the levels of cleaved caspase-3 was
observed among transduced and untransduced primary
neurons.
Supplemental Figure 2 | MMP+ treatment induced neurotoxicity and
alterations in major signaling cascades in both untransduced and
scramble miR transduced cortical neurons in a similar manner. (A) Six to
seven days old primary cortical neurons were left untreated or were
transduced with adenoviral particles expressing scramble miR. After 24 h,
neuronal cultures were exposed for additional 24 h to various
concentrations of MPP+. Cell viability following dose-dependent
treatments was assayed by measuring MTT reduction by live neurons.
Note that similar significant reductions in neuronal viability was observed
in both untransduced and scramble miR transduced neurons upon
treatment with 10, 20, 30, and 50μM, but not 5μM, of MPP+. (B,C) Six
to seven days old primary cortical neurons were left untreated or were
transduced with adenoviral particles expressing scramble miR. After 24 h,
neuronal cultures were exposed for additional 24 h to 10μM of MPP+.
Equal amounts of total protein from lysates of cortical neurons were
analyzed on 10% SDS-PAGE and immunoblotted with antibodies specific
for phosphorylated forms of AKT, p38 MAPK, p70S6K, SAPK/JNK, and
ERK1/2. To ensure equal loading membranes were re-probed against AKT,
p38 MAPK, p70S6K, SAPK/JNK, and ERK1/2, respectively. Note that in
contrast to untransduced neurons, scramble miR transduced neurons
displayed significant reduction of phosphorylated AKT levels even at
10μM of MPP+. No difference was observed in the phosphorylation
status of the other major signaling kinases examined among
untransduced and scramble miR transduced neurons upon treatment with
10μM of MPP+. ∗∗∗P < 0.001.
Supplemental Figure 3 | Adenoviral overexpression of miR-7 and miR-153
in cortical neurons, but not of scramble miR, activated p70S6K signaling
cascade. Six to seven days old primary cortical neurons were transduced
with empty adenoviral particles or adenoviral particles expressing
scramble miR, miR-7, or miR-153 and were lysed 48 later. Equal amounts
of total protein from lysates of untransduced and transduced cortical
neurons were analyzed on 10% SDS-PAGE and immunoblotted with
antibodies specific for phosphorylated forms of p70S6K (A) and S6RP (B).
To ensure equal loading, membranes were re-probed against GAPDH.
Note that no difference was observed in the levels of phosphorylated
p70S6K and S6RP between transduced empty control and scramble miR
transduced cortical neurons.
Supplemental Figure 4 | Rapamycin induced neurotoxicity in cortical
neurons. Seven-day primary cortical neurons were treated with various
concentrations of rapamycin and MPP+ for 24 h. Cell viability following
dose-dependent treatments was assayed by measuring MTT reduction by
live neurons. Note that a significant ∼20% reduction in neuronal viability
was observed upon treatment with rapamycin at concentrations
20–50 nM [F(4, 14) = 20.852, P < 0.001]. No synergistic effect was
observed among rapamycin and MPP+. ∗∗∗P < 0.001.
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